217 related articles for article (PubMed ID: 7669063)
1. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase.
Anlezark GM; Melton RG; Sherwood RF; Wilson WR; Denny WA; Palmer BD; Knox RJ; Friedlos F; Williams A
Biochem Pharmacol; 1995 Aug; 50(5):609-18. PubMed ID: 7669063
[TBL] [Abstract][Full Text] [Related]
2. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
Johansson E; Parkinson GN; Denny WA; Neidle S
J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
[TBL] [Abstract][Full Text] [Related]
3. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.
Helsby NA; Ferry DM; Patterson AV; Pullen SM; Wilson WR
Br J Cancer; 2004 Mar; 90(5):1084-92. PubMed ID: 14997211
[TBL] [Abstract][Full Text] [Related]
4. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.
Helsby NA; Wheeler SJ; Pruijn FB; Palmer BD; Yang S; Denny WA; Wilson WR
Chem Res Toxicol; 2003 Apr; 16(4):469-78. PubMed ID: 12703963
[TBL] [Abstract][Full Text] [Related]
5. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase.
Knox RJ; Friedlos F; Sherwood RF; Melton RG; Anlezark GM
Biochem Pharmacol; 1992 Dec; 44(12):2297-301. PubMed ID: 1472095
[TBL] [Abstract][Full Text] [Related]
6. Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT).
Knox RJ; Friedlos F; Jarman M; Davies LC; Goddard P; Anlezark GM; Melton RG; Sherwood RF
Biochem Pharmacol; 1995 May; 49(11):1641-7. PubMed ID: 7786305
[TBL] [Abstract][Full Text] [Related]
7. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT).
Anlezark GM; Melton RG; Sherwood RF; Coles B; Friedlos F; Knox RJ
Biochem Pharmacol; 1992 Dec; 44(12):2289-95. PubMed ID: 1472094
[TBL] [Abstract][Full Text] [Related]
8. Bacillus amyloliquefaciens orthologue of Bacillus subtilis ywrO encodes a nitroreductase enzyme which activates the prodrug CB 1954.
Anlezark GM; Vaughan T; Fashola-Stone E; Paul Michael N; Murdoch H; Sims MA; Stubbs S; Wigley S; Minton NP
Microbiology (Reading); 2002 Jan; 148(Pt 1):297-306. PubMed ID: 11782522
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells.
Palmer BD; Wilson WR; Cliffe S; Denny WA
J Med Chem; 1992 Aug; 35(17):3214-22. PubMed ID: 1507207
[TBL] [Abstract][Full Text] [Related]
10. Prodrugs for Nitroreductase Based Cancer Therapy- 1: Metabolite Profile, Cell Cytotoxicity and Molecular Modeling Interactions of Nitro Benzamides with Ssap-NtrB.
Gungor T; Yetis G; Onder FC; Tokay E; Tok TT; Celik A; Ay M; Kockar F
Med Chem; 2018; 14(5):495-507. PubMed ID: 29189173
[TBL] [Abstract][Full Text] [Related]
11. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).
Knox RJ; Friedlos F; Boland MP
Cancer Metastasis Rev; 1993 Jun; 12(2):195-212. PubMed ID: 8375021
[TBL] [Abstract][Full Text] [Related]
12. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
Helsby NA; Atwell GJ; Yang S; Palmer BD; Anderson RF; Pullen SM; Ferry DM; Hogg A; Wilson WR; Denny WA
J Med Chem; 2004 Jun; 47(12):3295-307. PubMed ID: 15163209
[TBL] [Abstract][Full Text] [Related]
13. CB 1954: from the Walker tumor to NQO2 and VDEPT.
Knox RJ; Burke PJ; Chen S; Kerr DJ
Curr Pharm Des; 2003; 9(26):2091-104. PubMed ID: 14529407
[TBL] [Abstract][Full Text] [Related]
14. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy.
Bailey SM; Knox RJ; Hobbs SM; Jenkins TC; Mauger AB; Melton RG; Burke PJ; Connors TA; Hart IR
Gene Ther; 1996 Dec; 3(12):1143-50. PubMed ID: 8986441
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
[TBL] [Abstract][Full Text] [Related]
16. Nitroreductase-based GDEPT.
Denny WA
Curr Pharm Des; 2002; 8(15):1349-61. PubMed ID: 12052212
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis (2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase.
Atwell GJ; Boyd M; Palmer BD; Anderson RF; Pullen SM; Wilson WR; Denny WA
Anticancer Drug Des; 1996 Oct; 11(7):553-67. PubMed ID: 8921936
[TBL] [Abstract][Full Text] [Related]
18. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.
Wilson WR; Pullen SM; Hogg A; Helsby NA; Hicks KO; Denny WA
Cancer Res; 2002 Mar; 62(5):1425-32. PubMed ID: 11888915
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5.
Kestell P; Pruijn FB; Siim BG; Palmer BD; Wilson WR
Cancer Chemother Pharmacol; 2000; 46(5):365-74. PubMed ID: 11127940
[TBL] [Abstract][Full Text] [Related]
20. Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954.
Race PR; Lovering AL; White SA; Grove JI; Searle PF; Wrighton CW; Hyde EI
J Mol Biol; 2007 Apr; 368(2):481-92. PubMed ID: 17350040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
